Medherant
Medherant develops transdermal drug patch products based on our next-generation TEPI-Patch® transdermal drug technology. Our lead product, a testosterone patch for women, is currently in the clinic.
Key advantages of the TEPI Patch® technology are high adhesion (up to 7 days) without irritation and with no pain on removal; patches are thin, flexible and comfortable; and they are water resistant and leave no residues or dirty marks. In addition, no solvents are required for the manufacturing processes.
As well as developing our own products, Medherant is working with a major multinational company to develop a multi-day patch for one of their drugs. We offer rapid feasibility studies to other companies interested in exploring the potential to develop transdermal formulations of their drugs of interest.
Nigel Davis
Chief Business Officer
John Burt
Chief Executive Officer
MediWales
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
Debbie Laubach
Operations Director
